FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914906564> ?p ?o ?g. }

• W2914906564 endingPage "3129" @default.
• W2914906564 startingPage "3129" @default.
• W2914906564 abstract "Abstract Background: Chromosome 14q32 rearrangements involving the immunoglobulin heavy chain gene (IGH) affect less than 5% of chronic lymphocytic leukemia (CLL) patients. Their clinical course is aggressive and the outcome, worse than other CLL subtypes (Cavazzini et al, 2008; Gerrie et al, 2012). However, the biology of CLL showing IGH rearrangements (CLL-IGHR) is not completely defined. The identification of novel recurrent mutations in CLL by next generation-sequencing (NGS) has offered a more comprehensive view into the genomic landscape of the disease and improved the prognostication of CLL. Thus, mutational analysis might be especially useful in those patients with uncertain prognosis, such as those carrying IGH rearrangements. Aim: To analyze the mutational profile of CLL-IGHR patients by targeted NGS in order to improve our understanding of the genetic underpinnings of this subgroup. Methods: The study was based on 899 CLL patients, well characterized at cytogenetic, biological and clinical level, forty-two of them (4.7%) showing IGH rearrangements. Targeted NGS was performed in 231 CLL samples: 117 with 13q deletion, 27 with 11q deletion, 26 trisomy 12, 42 showing IGH rearrangements and the remaining 19 without any cytogenetic alteration. CD19+ B cells were isolated and DNA extracted. SureSelectQXT targeted enrichment technology and a custom-designed panel (MiSeq, Illumina), including 54 CLL-related and recurrent mutated genes, was carried out. The panel yielded 100x or greater coverage on 97% of the genomic regions of interest and the mean coverage obtained was 600x. Mutations were detected down to 3% allele frequency. Results: The mutational analysis of CLL-IGHR patients identified a total of 72 mutations in 32 genes. Seventy-one percent of patients (30/42) harbored at least one mutation. The most frequently mutated genes in this cohort were NOTCH1 (28.6%), POT1 (14.3%), TP53 (9.5%), SF3B1 (7%), BRAF (7%), EGR2 (7%), IGLL5 (7%) and MGA (7%), followed by BCL2, HIST1H1E and FBXW7 (4.8%), uncommonly mutated genes in CLL at these frequencies (Table 1). In fact, mutations in NOTCH1, BRAF, EGR2, BCL2, HIST1H1E and FBXW7 were significantly associated with CLL-IGHR patients (p=0.013, p=0.003, p=0.021, p=0.038, p=0.038 and p=0.021 respectively). In terms of time to the first therapy (TFT), CLL-IGHR had an intermediate-negative impact (median TFT=24 months) compared to the presence of cytogenetic alterations associated with good prognosis such as 13q deletions (median TFT>120 months; p<0.0001) (Figure 1A). Furthermore, the presence of mutations in the most frequently mutated genes (NOTCH1, POT1, TP53, SF3B1 or BRAF) within patients with IGH rearrangements had a negative clinical impact in the TFT and allowed us to refine the prognosis of this subgroup. Thus, the median TFT of patients with mutations was 1 month while the median TFT of patients without mutations was 14 months (p=0.014) (Figure 1B). A total of 17 out of 42 CLL-IGHR patients (40.5%) carried the t(14;18). Interestingly, patients with t(14;18) were characterized by: 1) A lower mutation frequency (average of mutations/patient=1.05) than the rest of rearrangements with unknown partners (average=2.16; p=0.039), and 2) The presence of mutations in BCL2 (11%) and HIST1H1E (11%). By contrast, CLL-IGHR without BCL2 rearrangement showed mutations in POT1 (20%), TP53 (16%), SF3B1 (12%) and BRAF (12%). Moreover, t(14;18) was significantly associated with good prognosis markers such as the mutated status of the variable region of the immunoglobulin genes (IGHV-M) (p=0.002). However, there was no significant difference in terms of TFT between patients with t(14;18) and patients with other IGH rearrangements (p=0.27). Conclusions: CLL patients with IGH rearrangements showed: i. A high gene mutation frequency; ii. A distinct mutational profile, with recurrent mutations in POT1, EGR2, BRAF, IGLL5 and MGA genes; iii. An adverse clinical outcome refined by the negative effect of genetic mutations. iv. Patients with t(14;18) presented a lower mutation frequency than the rest of rearrangements, carrying mutations in BCL2 and HIST1H1E, and associated with good-prognosis markers such as IGHV-M. Funding:PI15/01471; CIBERONC CB16/12/00233; FEHH-Janssen(MHS); JCyL(MQÁ) Disclosures Mateos: Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees." @default.
• W2914906564 created "2019-02-21" @default.
• W2914906564 creator A5012402337 @default.
• W2914906564 creator A5013709600 @default.
• W2914906564 creator A5017590866 @default.
• W2914906564 creator A5022013234 @default.
• W2914906564 creator A5029159537 @default.
• W2914906564 creator A5034771058 @default.
• W2914906564 creator A5040268432 @default.
• W2914906564 creator A5040387233 @default.
• W2914906564 creator A5040945039 @default.
• W2914906564 creator A5041612097 @default.
• W2914906564 creator A5050004865 @default.
• W2914906564 creator A5055033732 @default.
• W2914906564 creator A5059408277 @default.
• W2914906564 creator A5059635260 @default.
• W2914906564 creator A5060740704 @default.
• W2914906564 creator A5060880185 @default.
• W2914906564 creator A5061553190 @default.
• W2914906564 creator A5064854422 @default.
• W2914906564 creator A5069688230 @default.
• W2914906564 creator A5074746066 @default.
• W2914906564 creator A5078766249 @default.
• W2914906564 creator A5080348867 @default.
• W2914906564 date "2018-11-29" @default.
• W2914906564 modified "2023-10-03" @default.
• W2914906564 title "Chronic Lymphocytic Leukemia Patients with IGH Rearrangements Are Characterized By a Distinct Genetic Landscape with Prognostic Implications" @default.
• W2914906564 doi "https://doi.org/10.1182/blood-2018-99-115959" @default.
• W2914906564 hasPublicationYear "2018" @default.
• W2914906564 type Work @default.
• W2914906564 sameAs 2914906564 @default.
• W2914906564 citedByCount "0" @default.
• W2914906564 crossrefType "journal-article" @default.
• W2914906564 hasAuthorship W2914906564A5012402337 @default.
• W2914906564 hasAuthorship W2914906564A5013709600 @default.
• W2914906564 hasAuthorship W2914906564A5017590866 @default.
• W2914906564 hasAuthorship W2914906564A5022013234 @default.
• W2914906564 hasAuthorship W2914906564A5029159537 @default.
• W2914906564 hasAuthorship W2914906564A5034771058 @default.
• W2914906564 hasAuthorship W2914906564A5040268432 @default.
• W2914906564 hasAuthorship W2914906564A5040387233 @default.
• W2914906564 hasAuthorship W2914906564A5040945039 @default.
• W2914906564 hasAuthorship W2914906564A5041612097 @default.
• W2914906564 hasAuthorship W2914906564A5050004865 @default.
• W2914906564 hasAuthorship W2914906564A5055033732 @default.
• W2914906564 hasAuthorship W2914906564A5059408277 @default.
• W2914906564 hasAuthorship W2914906564A5059635260 @default.
• W2914906564 hasAuthorship W2914906564A5060740704 @default.
• W2914906564 hasAuthorship W2914906564A5060880185 @default.
• W2914906564 hasAuthorship W2914906564A5061553190 @default.
• W2914906564 hasAuthorship W2914906564A5064854422 @default.
• W2914906564 hasAuthorship W2914906564A5069688230 @default.
• W2914906564 hasAuthorship W2914906564A5074746066 @default.
• W2914906564 hasAuthorship W2914906564A5078766249 @default.
• W2914906564 hasAuthorship W2914906564A5080348867 @default.
• W2914906564 hasBestOaLocation W29149065641 @default.
• W2914906564 hasConcept C104317684 @default.
• W2914906564 hasConcept C113968399 @default.
• W2914906564 hasConcept C2776229224 @default.
• W2914906564 hasConcept C2777609679 @default.
• W2914906564 hasConcept C2777938653 @default.
• W2914906564 hasConcept C2778461978 @default.
• W2914906564 hasConcept C2992511266 @default.
• W2914906564 hasConcept C501734568 @default.
• W2914906564 hasConcept C502942594 @default.
• W2914906564 hasConcept C54355233 @default.
• W2914906564 hasConcept C86803240 @default.
• W2914906564 hasConcept C96007430 @default.
• W2914906564 hasConceptScore W2914906564C104317684 @default.
• W2914906564 hasConceptScore W2914906564C113968399 @default.
• W2914906564 hasConceptScore W2914906564C2776229224 @default.
• W2914906564 hasConceptScore W2914906564C2777609679 @default.
• W2914906564 hasConceptScore W2914906564C2777938653 @default.
• W2914906564 hasConceptScore W2914906564C2778461978 @default.
• W2914906564 hasConceptScore W2914906564C2992511266 @default.
• W2914906564 hasConceptScore W2914906564C501734568 @default.
• W2914906564 hasConceptScore W2914906564C502942594 @default.
• W2914906564 hasConceptScore W2914906564C54355233 @default.
• W2914906564 hasConceptScore W2914906564C86803240 @default.
• W2914906564 hasConceptScore W2914906564C96007430 @default.
• W2914906564 hasIssue "Supplement 1" @default.
• W2914906564 hasLocation W29149065641 @default.
• W2914906564 hasOpenAccess W2914906564 @default.
• W2914906564 hasPrimaryLocation W29149065641 @default.
• W2914906564 hasRelatedWork W1874932452 @default.
• W2914906564 hasRelatedWork W2063710350 @default.
• W2914906564 hasRelatedWork W2149869428 @default.
• W2914906564 hasRelatedWork W2152046779 @default.
• W2914906564 hasRelatedWork W2157596388 @default.
• W2914906564 hasRelatedWork W2792151563 @default.
• W2914906564 hasRelatedWork W2914906564 @default.
• W2914906564 hasRelatedWork W3115057018 @default.
• W2914906564 hasRelatedWork W4285392978 @default.
• W2914906564 hasRelatedWork W4308187183 @default.
• W2914906564 hasVolume "132" @default.
• W2914906564 isParatext "false" @default.
• W2914906564 isRetracted "false" @default.
• W2914906564 magId "2914906564" @default.

• next